Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Sintilimab and Chemotherapy in Advanced ESCC
NCT06718205Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Started Mar 2023; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06718205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06718205.